This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Exubera

Nektar Therapeutics

Drug Names(s): inhaled insulin, CP-464,005

Description: Exubera is an inhaled, rapid-acting, dry-powder insulin.

Deal Structure: Nektar entered into a collaborative agreement with Pfizer in January 1995 under which it is developing Exubera with Pfizer and their collaborator Sanofi-Aventis.

In addition to receiving revenues for the manufacture and supply of drug powders and inhalers, Nektar will receive a royalty on inhalable insulin products marketed jointly by Pfizer and Sanofi-Aventis.

In November 1998, Pfizer and Aventis announced that they entered into a worldwide agreement to manufacture insulin and to co-develop and co-promote inhaleable insulin. Under the terms of the agreement, Pfizer and Aventis constructed a jointly owned insulin manufacturing plant in Frankfurt, Germany.

In 2004, Sanofi-Synthelabo acquired Aventis to create Sanofi-Aventis. Pfizer and Sanofi-Aventis are engaged in litigation with respect to their agreement to manufacture insulin and to co-develop and co-promote inhaleable insulin. Nektar is not a party to this litigation.

In January 2006, Pfizer announced the...See full deal structure in Biomedtracker

Partners: Pfizer Inc.


Exubera News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug